Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neoadjuvant chemotherapy (NAC) to predict chemotherapy response before interval debulking surgery (IDS) in advanced-stage ovarian cancer patients. Materials and Methods Forty consecutive patients underwent 18F-FDG-PET/CT at baseline and after one cycle of NAC. Metabolic responses were assessed by quantitative decrease in the maximum standardized uptake value (SUVmax) with PET/CT. Decreases in SUVmax were compared with cancer antigen 125 (CA-125) level before IDS, response rate by Response Evaluation Criteria in Solid Tumors criteria before IDS, residual tumor at IDS, and I chemotherapy response score (CRS) at IDS. Results A 40% cut-off for the decrease in SUVmax provided the best performance to predict CRS 3 (compete or near-complete pathologic response), with sensitivity, specificity, and accuracy of 81.8%, 72.4%, and 72.4%, respectively. According to this 40% cut-off, there were 17 (42.5%) metabolic responders (≥ 40%) and 23 (57.5%) metabolic non-responders (< 40%). Metabolic responders had higher rate of CRS 3 (52.9% vs. 8.7%, p=0.003), CA-125 normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, p=0.019), and no residual tumor at IDS (70.6% vs. 31.8%, p=0.025) compared with metabolic non-responders. There were significant associations with progression-free survival (p=0.021) between metabolic responders and non-responders, but not overall survival (p=0.335). Conclusion Early assessment with 18F-FDG-PET/CT after one cycle of NAC can be useful to predic response to chemotherapy before IDS in patients with advanced-stage ovarian cancer.
Abstract
Purpose The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neoadjuvant chemotherapy (NAC) to predict chemotherapy response before interval debulking surgery (IDS) in advanced-stage ovarian cancer patients. Materials and Methods Forty consecutive patients underwent 18F-FDG-PET/CT at baseline and after one cycle of NAC. Metabolic responses were assessed by quantitative decrease in the maximum standardized uptake value (SUVmax) with PET/CT. Decreases in SUVmax were compared with cancer antigen 125 (CA-125) level before IDS, response rate by Response Evaluation Criteria in Solid Tumors criteria before IDS, residual tumor at IDS, and I chemotherapy response score (CRS) at IDS. Results A 40% cut-off for the decrease in SUVmax provided the best performance to predict CRS 3 (compete or near-complete pathologic response), with sensitivity, specificity, and accuracy of 81.8%, 72.4%, and 72.4%, respectively. According to this 40% cut-off, there were 17 (42.5%) metabolic responders (≥ 40%) and 23 (57.5%) metabolic non-responders (< 40%). Metabolic responders had higher rate of CRS 3 (52.9% vs. 8.7%, p=0.003), CA-125 normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, p=0.019), and no residual tumor at IDS (70.6% vs. 31.8%, p=0.025) compared with metabolic non-responders. There were significant associations with progression-free survival (p=0.021) between metabolic responders and non-responders, but not overall survival (p=0.335). Conclusion Early assessment with 18F-FDG-PET/CT after one cycle of NAC can be useful to predic response to chemotherapy before IDS in patients with advanced-stage ovarian cancer.
참고문헌 (24)
- Kehoe S, "Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS) : an open-label, randomised, controlled, non-inferiority trial", Lan-cet, 386, pp.249~257 (2015)
- Vergote I, "Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer", N Engl J Med, 363, pp.943~953 (2010)
- Groheux D, "Early assessment with 18F-fluorodeoxyglucose posi-tron emission tomography", computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer, 2014, pp.50, 1864~1871
- Lordick F, "PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction : the MUNICON phase II trial", Lancet Oncol, 8, pp.797~805 (2007)
- Evilevitch V, "Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas", Clin Cancer Res, 14, pp.715~720 (2008)
- Kostakoglu L, "PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus", J Nucl Med, 45, pp.56~68 (2004)
- MacManus MP, "Overview of early response assessment in lymphoma with FDG-PET", Cancer Imaging, 7, pp.10~18 (2007)
- Burger IA, "Correlation between therapy response assessment using FDG PET", CT and histopathologic tumor regression grade in hepatic metastasis of colorectal carcinoma after neoadjuvant therapy, 2013, pp.27, 177~183
- 박준석, "Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma", Cancer Research and Treatment, 45(1), pp.22~30 (2013), 대한암학회[DOI]
- Avril N, "Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer", J Clin Oncol, 23, pp.7445~7453 (2005)
- Nishiyama Y, "Monitoring the neoadjuvant therapy res-ponse in gynecological cancer patients using FDG PET", Eur J Nucl Med Mol Imaging, 35, pp.287~295 (2008)
- FDG-PET, "CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy", Q J Nucl Med Mol Imaging, 55, pp.81~90 (2011)
- Vallius T, "18F-FDG-PET", CT can identify histopathological non-responders to platinum-based neoadjuvant che-motherapy in advanced epithelial ovarian cancer, 2016, pp.140, 29~35
- Muraji M, "Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neo-adjuvant chemotherapy and debulking surgery", Gynecol Oncol, 131, pp.531~534 (2013)
- Petrillo M, "Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer", Am J Obstet Gynecol, 211, pp.632~ (2014)
- Le T, "Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debul-king", Gynecol Oncol, 106, pp.160~163 (2007)
- Sassen S, "Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer", Hum Pathol, 38, pp.926~934 (2007)
- Bohm S, "Chemotherapy response score : development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma", J Clin Oncol, 33, pp.2457~2463 (2015)
- 이정윤, "External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma", Journal of Gynecologic Oncology, 28(6), pp.1~9 (2017), 대한부인종양학회[DOI]
- Fagotti A, "Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma", Am J Obstet Gynecol, 199, pp.642~ (2008)
- 이용재, "Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study", Journal of Gynecologic Oncology, 30(1), pp.1~11 (2019), 대한부인종양학회[DOI]
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Wahl RL, "From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors", J Nucl Med, 50(Suppl 1), pp.122S~150S (2009)
- Lee JY, "Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing", BMC Cancer, 15, pp.85~ (2015)